Institutional members access full text with Ovid®

Share this article on:

Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy

Corrao, Giovannia; Zambon, Antonellaa; Parodi, Andreaa; Poluzzi, Elisabettab; Baldi, Ileanac; Merlino, Lucad; Cesana, Giancarloe; Mancia, Giuseppef

doi: 10.1097/HJH.0b013e3282f4edd7
Original papers: Therapeutic aspects

Objectives To assess rates and determinants of treatment discontinuation of or changes in initial antihypertensive drug therapy in a large cohort of patients from Lombardia (Italy).

Methods The cohort included 445 356 patients aged 40 –80 years who received their first antihypertensive drug prescription (monotherapy) during 1999–2002. Discontinuation was defined by the absence of any antihypertensive prescription during a 90-day period following the end of the latest prescription. If during the same period a drug of a different class was added or replaced the initial prescription, treatment modification was regarded as combination or switching, respectively. Competing risks methodology was used to estimate and compare cause-specific cumulative incidence.

Results Cumulative incidences of discontinuation, combination and switching were respectively 33, 14 and 15% at 6 months, 41, 18 and 17% at 1 year, and 50, 25 and 19% at 5 years since initial treatment. Compared with patients starting treatment with angiotensin-converting enzyme inhibitors, the rate of discontinuation was less for patients on angiotensin receptor blockers with a hazard ratio of 0.92 (95% confidence interval =0.90-0.94), whereas increased discontinuation was observed for patients starting with other drugs, mainly β-blockers with a hazard ratio of 1.64 (1.62-1.67); and diuretics with a hazard ratio of 1.83 (1.81-1.85).

Conclusion In the general population of Lombardia, discontinuation of the initial single antihypertensive drug treatment is a common phenomenon, whereas switching to another monotherapy and to combination treatment occur at similarly much lower rates. Blockers of the renin-angiotensin system are associated with the lowest incidence of treatment discontinuation.

aDepartment of Statistics, Unit of Biostatistics and Epidemiology, University of Milano-Bicocca, Milan, Italy

bDepartment of Pharmacology, University of Bologna, Bologna, Italy

cCentre for Cancer Prevention (CPO), Region Piemonte, Turin, Italy

dOperative Unit of Territorial Health Services, Region Lombardia, Milan, Italy

eResearch Center on Chronic Degenerative Diseases, University of Milan-Bicocca, Milan, Italy

fDepartment of Medicine, Prevention and Health Biotechnology, University of Milano-Bicocca, Milan, Italy

Received 12 July, 2007

Revised 16 November, 2007

Accepted 29 November, 2007

Correspondence to Professor Giovanni Corrao. Dipartimento di Statistica. Unità di Biostatistica ed Epidemiologia, Università degli Studi di Milano-Bicocca. Via Bicocca degli Arcimboldi, 8, Edificio U7, 20126 Milano, Italy Tel: +39 02 64485854; fax: +39 02 64485899; e-mail:

© 2008 Lippincott Williams & Wilkins, Inc.